A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
详细信息 查看全文
- 作者：Joel M. Kremer ; Paul Emery ; Heidi S. Camp ; Alan Friedman ; Li Wang ; Ahmed A. Othman ; Nasser Khan ; Aileen L. Pangan ; Steven Jungerwirth and Edward C. Keystone
- 刊名：Arthritis & Rheumatism
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：68
- 期：12
- 页码：2867-2877
- 全文大小：366K
- ISSN：1529-0131
文摘
To compare the efficacy and safety of ABT-494, a novel selective JAK-1 inhibitor, with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response or intolerance to at least 1 anti–tumor necrosis factor (anti-TNF) agent.